<DOC>
	<DOCNO>NCT02044146</DOCNO>
	<brief_summary>In patient heart attack , treatment choice restore blood flow percutaneous coronary intervention ( PCI ) ( use stent ( metal mesh ) open blockage ) . After PCI , standard drug treatment include aspirin clopidogrel . These medication block full function platelet cell , responsible clotting . Despite use , patient PCI risk heart attack , sudden clotting stent death . A major contributor may resistance clopidogrel . New potent drug , overcome resistance , available ; however , come increase chance severe bleeding cost . An ideal solution would identify at-risk patient selectively treat potent drug , lower-risk patient continue clopidogrel . This type strategy ( personalize strategy ) would decrease heart attack death ( compare clopidogrel ) , also prevent bleed complication ( compare treat patient new drug ) . Of resistant patient , many carry gene ( inherit unit ) prevent proper absorption clopidogrel . Our group develop test new bedside genetic test , identify carrier at-risk gene . However , technique alone identify at-risk patient . Consequently , devise novel tool , combine genetics patient characteristic identify high-risk patient . The present study combine new tool strategy personalize treatment . Patients heart attack undergo PCI randomly assign 1 3 strategy : ) new personalize strategy , b ) clopidogrel strategy ( previous standard drug ) c ) ticagrelor strategy ( strong approve drug ) . The function platelet cell measure 1 month determine potential benefit . Evaluation new personalize strategy important improve patient outcome PCI . The hypothesis patient receive personalized strategy decrease risk future heart attack bleed .</brief_summary>
	<brief_title>A Pharmacodynamic Study Personalized Strategy P2Y12 Inhibition Versus Ticagrelor Reducing Ischemic Bleeding Risk</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients : age &gt; 18 yr , &lt; 75yrs &gt; 60 kg ( since March 2015 age &gt; 75 &lt; 60 kg eligible prasugrel reduce 5mg daily randomize personalized therapy arm ) NSTEMI undergo PCI eligible Patients exclude : ) contraindication clopidogrel prasugrel ticagrelor ( per monograph ) , ii ) intolerance aspirin , iii ) absolute requirement ticagrelor prasugrel ( e.g . stent thrombosis , allergic reaction clopidogrel ) , iv ) requirement anticoagulation treatment , v ) history stroke , TIA intracranial hemorrhage , vi ) platelet count &lt; 100,000/Î¼l , vii ) know bleed diathesis , viii ) hematocrit &lt; 30 % &gt; 52 % , ix ) severe liver dysfunction , x ) renal insufficiency ( creatinine clearance &lt; 30ml/min ) , xi ) adjuvant therapy glycoprotein IIbIIIa inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>